Photo: Dr. Doug Thamm examines Jake, a labrador that took part in VetDC’s Tanovea clinical trials at the Flint Animal Cancer Center at CSU. Courtesy John Eisele/ CSU.
By Doug Storum — April 4, 2017
From Bizwest
FORT COLLINS — VetDC, a veterinary cancer-therapeutics company based in Fort Collins, said Monday that it has begun selling its drug that treats lymphoma in dogs to licensed veterinarians in the United States.
Steven Roy, VetDC’s president and chief executive, said the company activated its ordering platform last week.
“Orders started coming in immediately from clinics that had been following the clinical trials,” Roy said. “There is a pent-up demand for this this type of drug.”
Piramal Pharma Solutions Inc. in Lexington, Ken., is manufacturing the drug for VetDC. Piramal will be able to ramp up production to match orders as they come in, Roy said.
The drug is sold to veterinary clinics in a powder form that is reconstituted to a liquid. It is administered intravenously for 30 minutes per session.
“We believe Tanovea-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology, said Dr. Terry Opgenorth, vice president of CSU Ventures and a co-founder of VetDC.
Dr. Craig Clifford, a veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, Pa., said, based on first-hand experience as part of clinical trials, the drug has the potential to become a cornerstone for the treatment of lymphoma in dogs.
The U.S. Food and Drug Administration’s Center for Veterinary Medicine in January granted conditional approval for the drug, two months after VetDC filed an application.
(Updated January 10, 2018) For more information on Tanovea-CA1, please follow this link.
